Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.53 |
| ▸ | P2RY12 | Q9H244 | 11/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876930 | 0.88 | P2RY12 (0.49) | OPRK1P2RY12CYP2C9CYP3A4MAPT | |
| SCHEMBL3328130 | 0.87 | MEN1 (0.44) | OPRK1P2RY12CYP2C9CYP3A4CHRM2 | |
| SCHEMBL4877258 | 0.86 | OPRK1 (0.59) | OPRK1P2RY12CYP2C9CYP3A4CHRM2 | |
| SCHEMBL4115190 | 0.84 | P2RY12 (0.70) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4742022 | 0.81 | OPRK1 (0.39) | OPRK1P2RY12CYP2C9CYP3A4CHRM2 | |
| SCHEMBL4874293 | 0.81 | P2RY12 (0.78) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4739435 | 0.80 | HSD11B1 (0.42) | OPRK1P2RY12CYP2C9CYP3A4CHRM2 | |
| SCHEMBL3933293 | 0.80 | P2RY12 (0.62) | P2RY12 | |
| SCHEMBL3327301 | 0.78 | MAPT (0.49) | OPRK1P2RY12MAPTKDM4ENPSR1 | |
| SCHEMBL30999839 | 0.78 | P2RY12 (0.65) | P2RY12CYP2C9CYP3A4CHRM2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| CN-101263133-A | New pyridine analogues | ASTRAZENECA AB (SE) | 2008-09-10 | — | — | CN | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | OPRK1 1862/4885P2RY12 1/4885CYP2C9 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.